Isosteviol Has Beneficial Effects on Palmitate-Induced α-Cell Dysfunction and Gene Expression by Chen, Xiaoping et al.
Isosteviol Has Beneficial Effects on Palmitate-Induced a-
Cell Dysfunction and Gene Expression
Xiaoping Chen
1,2, Kjeld Hermansen
1, Jianzhong Xiao
2, Sara Kjaergaard Bystrup
1, Lorraine O’Driscoll
3,
Per Bendix Jeppesen
1*
1The Department of Endocrinology and Metabolism MEA, Aarhus University Hospital, Aarhus, Denmark, 2Department of Endocrinology, China-Japan Friendship Hospital,
Beijing, China, 3School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
Abstract
Background: Long-term exposure to high levels of fatty acids impairs insulin secretion and exaggerates glucagon secretion.
The aim of this study was to explore if the antihyperglycemic agent, Isosteviol (ISV), is able to counteract palmitate-induced
a-cell dysfunction and to influence a-cell gene expression.
Methodology/Principal Findings: Long-term incubation studies with clonal a-TC1–6 cells were performed in the presence
of 0.5 mM palmitate with or without ISV. We investigated effects on glucagon secretion, glucagon content, cellular
triglyceride (TG) content, cell proliferation, and expression of genes involved in controlling glucagon synthesis, fatty acid
metabolism, and insulin signal transduction. Furthermore, we studied effects of ISV on palmitate-induced glucagon
secretion from isolated mouse islets. Culturing a-cells for 72-h with 0.5 mM palmitate in the presence of 18 mM glucose
resulted in a 56% (p,0.01) increase in glucagon secretion. Concomitantly, the TG content of a-cells increased by 78%
(p,0.01) and cell proliferation decreased by 19% (p,0.05). At 18 mM glucose, ISV (10
28 and 10
26 M) reduced palmitate-
stimulated glucagon release by 27% (p,0.05) and 27% (p,0.05), respectively. ISV (10
26 M) also counteracted the palmitate-
induced hypersecretion of glucagon in mouse islets. ISV (10
26 M) reduced a-TC1–6 cell proliferation rate by 25% (p,0.05),
but ISV (10
28 and 10
26 M) had no effect on TG content in the presence of palmitate. Palmitate (0.5 mM) increased Pcsk2
(p,0.001), Irs2 (p,0.001), Fasn (p,0.001), Srebf2 (p,0.001), Acaca (p,0.01), Pax6 (p,0.05) and Gcg mRNA expression
(p,0.05). ISV significantly (p,0.05) up-regulated Insr, Irs1, Irs2, Pik3r1 and Akt1 gene expression in the presence of
palmitate.
Conclusions/Significance: ISV counteracts a-cell hypersecretion and apparently contributes to changes in expression of key
genes resulting from long-term exposure to palmitate. ISV apparently acts as a glucagonostatic drug with potential as a new
anti-diabetic drug for the treatment of type 2 diabetes.
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Introduction
Nearly four decades ago, the bihormonal-abnormality hypoth-
esis [1] established the essential role for glucagon in diabetes, by
highlighting the contributions of deficient insulin secretion,
development of insulin resistance and increased glucagon secretion
to the hyperglycemic state in type 2 diabetes. Glucagon, secreted
from the pancreatic a-cells, plays a critical role in the regulation of
glycemia [2]. This hormone counteracts hypoglycemia and
opposes insulin actions by stimulating hepatic glucose synthesis
and mobilization, thereby increasing blood glucose concentrations
[3]; a large body of evidence shows that hyperglucagonemia is
essential to the maintenance of increased rates of hepatic glucose
output in type 2 diabetes [4,5].
Elevated levels of free fatty acid (FFA) are apparent in patients
with diabetes and prediabetes, suggesting that FFAs may be
involved in the pathophysiology of type 2 diabetes [6–8]. The
information on the effects of FFA on a-cells is sparse. It was
recently demonstrated that palmitate has an acute stimulating
effect on glucagon secretion from murine and rat islets [9,10]. We
have subsequently clarified that the acute fatty acid-induced
stimulation of glucagon secretion depends on the chain length,
spatial configuration, and degree of unsaturation of fatty acids
[11]. Interestingly, long-term exposure of clonal a-cells to
palmitate caused enhanced glucagon secretion and TG accumu-
lation in a time- and dose-dependent manner, while a-cell
proliferation was inhibited [12]. In agreement with this, long-
term exposure of rat islets to fatty acids elicited marked increase in
glucagon release, and decreased glucagon content; both appar-
ently without changing the glucagon gene expression [13].
However, the cellular and molecular mechanisms whereby
FFAs modulate the coupling of a-cell stimulus secretion remain an
enigma [14]. Understanding the mechanism(s) of FFAs action is of
potential importance for the development of novel, efficient
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(e.g. using GLP-1) or inhibiting glucagon action (e.g. with glucagon
receptor antagonists) have received much attention as therapeutic
strategies for the treatment of excess glucose production in type 2
diabetic patients [15,16].
Stevioside, a diterpene glycoside isolated from leaves of the
plant Stevia Rebaudiana Bertoni, represents a new class of insulin
secretagogues chemically unrelated to previous oral antidiabetic
drugs, such as sulphonylureas. Interestingly, we have shown that
stevioside is able to counteract a-cells hypersecretion caused by
palmitate and to enhance the expression of genes involved in fatty
acid metabolism [17]. Furthermore, we have demonstrated that
the stevioside derivate, ISV, has a higher bioavailability and a
higher potency on islet cell function and glycemic control when
compared to Stevioside, with the same low toxicity as Stevioside
[18].
The present study was, thus, designed to elucidate the potential
role of ISV on a-cell function and its effects on expression of
specific genes following long-term exposure to palmitate. Our
findings provide evidence that ISV decreases palmitate-induced
hyperglucagonemia in both the mouse pancreatic a-cell line,
aTC1–6 cells, and in isolated mice islets. ISV concomitantly
restores the palmitate-induced impairment of insulin secretion
from islets, affects intracellular insulin signal and a-cell prolifer-
ation.
Results
Impacts of ISV on palmitate-induced glucagon and
insulin secretion from isolated murine islets
To evaluate the impacts of ISV on the secretion of glucagon and
insulin from islets in the presence of palmitate, the isolated mouse
islets were cultured in medium supplemented with 0 mM
palmitate, 0.5 mM palmitate or 0.5 mM palmitate plus ISV
(10
26 M). To mimic hyperglycemia characteristic of the diabetic
state, the islets were incubated in fresh KRB medium containing
18 mM glucose for 2 h after incubating for 72 h in conditions as
described above. It was found that pre-treatment with palmitate
substantially increased glucose induced-glucagon secretion by 73%
(p,0.001; Fig. 1A) and suppressed glucose-stimulated insulin
secretion by 30% (p,0.01; Fig. 1B). In contrast, pre-treatment
with ISV (10
26 M) significantly suppressed palmitate-induced
hyper-secretion of glucagon by 32% (p,0.05; Fig. 1A), while it
ameliorated palmitate-suppressed insulin secretion by 38%
(p,0.05; Fig. 1B).
Effects of ISV short-term pretreatment on glucagon
secretion from palmitate-treated a- TC1–6 cells
After 2 h incubation with or without 0.5 mM palmitate in the
presence or absence of ISV (10
28 M and 10
26 M) at high glucose
(18 mM glucose), 0.5 mM palmitate increased glucagon secretion
by 52% (p,0.01; Fig. 2). Short-term pretreatment with ISV
(10
28 M and 10
26 M) had no effect on glucagon secretion by
palmitate-treated cells (Fig. 2). Glucagon secretion was unchanged
by ISV per se (Fig. 2).
Inhibitory effects of long-term pretreatment with ISV on
palmitate-induced glucagon secretion
Figure 3 demonstrates the effect of 72 h culture with ISV (10
28
and 10
26 M), without or with 0.5 mM palmitate, on glucagon
secretion in the presence of 2 mM glucose (Fig. 3A) or 18 mM
glucose (Fig. 3B), respectively. Palmitate resulted in a significant
stimulation of glucagon secretion both in the presence of low
(2 mM) and high (18 mM) glucose by 34% (p,0.05) and 56%
(p,0.01), respectively. ISV alone (10
28 and 10
26 M) had no effect
on glucagon secretion. However, in the presence of 0.5 mM
palmitate, the palmitate-induced glucagon release was inhibited by
18% (p,0.05) in the presence of 10
28 M ISV at 2 mM glucose.
Furthermore, at 18 mM glucose, glucagon secretion was de-
creased by 27% (p,0.05) and 27% (p,0.05), respectively, by
10
28 M and 10
26 M ISV.
Influence of palmitate and ISV on glucagon content
As illustrated at Figure 4A, we found a tendency toward
reduced glucagon content after 72 h culture with palmitate
(0.5 mM), however, this did not reach statistical significance.
ISV had no impact on glucagon content after 72 h culture with
0.5 mM palmitate.
Impact of palmitate and ISV on TG content
The effect of palmitate and ISV on TG content in a-TC1–6
cells cultured for 72 h is shown in Figure 4B. Palmitate
significantly increased intracellular TG content by 78%
(p,0.01), however, the addition of ISV (10
28 M, 10
26 M) in the
presence of palmitate had no impact on the TG content.
Impact of ISV on palmitate-induced changes on
3H-
thymidine incorporation
To determine whether the inhibitory effect of ISV on palmitate-
induced glucagon secretion could be mediated through cell
proliferation,
3H-thymidine incorporation was used to assess cell
proliferation. Within 72 h at 18 mM glucose, 0.5 mM palmitate
reduced the
3H-thymidine incorporation by 19% compared with
glucose alone (p,0.05). At 0.5 mM palmitate, 10
26 M ISV caused
a 25% (p,0.05; Fig. 4C) decrease in
3H-thymidine incorporation.
Effects of palmitate and ISV on gene expression
To gain further insight into the counteractive effect of ISV on
palmitate-induced hypersecretion of glucagon, the expression of a
few selected genes was examined in a-TC1–6 cells (Fig. 5).
Palmitate alone increased the expression of proprotein convertase
subtilisin/kexin type 2 (Pcsk2, p,0.001), insulin receptor substrate
2 (Irs2, p,0.001), fatty acid synthase (Fasn, p,0.001), sterol
regulatory element binding factor 2 (Srebf2, p,0.001), acetyl-
Coenzyme A carboxylase alpha (Acaca/ACC1, p,0.01), paired
box gene 6 (Pax6, p,0.05) and glucagon (Gcg, p,0.05). ISV alone
significantly increased expression of all the selected genes, in the
absence of palmitate (10
28 M, p,0.05; 10
26 M, p,0.001).
Compared with cells cultured with palmitate alone, cells cultured
with ISV (10
28 M) had a significantly higher expression of insulin
receptor (Insr), insulin receptor substrate 1 (Irs1), and phospha-
tidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)
(Pik3r1) genes in the presence of palmitate, while cells cultured
with a higher concentration of ISV (10
26 M) displayed signifi-
cantly higher expression levels of Irs1, Irs2, Pik3r1 and thymoma
viral proto-oncogene 1 (Akt1) gene in the presence of palmitate.
Glucagon receptor (Gcgr) gene expression was undetected in a-
TC1–6 cells (unpublished data).
Effects of a-cells and b-cells interaction on gene
expression
To investigate the interaction between a-cells and b-cells, a-
TC1–6 cells and MIN6 cells were co-cultured. The effects of co-
culture on the expression of the insulin1 (Ins1) and insulin2 (Ins2)
genes (specific to b-cells) and on the expression of Gcg gene
(specific to a-cells) were examined. The co-culturing was found to
Effects of Isosteviol on a-Cells
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Fig. 6A), Ins2 (p,0.01, Fig. 6B) and Gcg (p,0.001, Fig. 6C), as
compared with the independently culture of b-cells and a-cells.
Discussion
Here we have demonstrated that incubation of a-TC1–6 cells
for 72 h with 0.5 mM palmitate significantly increased their
glucagon secretion. Concomitantly, at high glucose concentrations
the TG content was increased, while a-TC1–6 cell proliferation
was decreased. In addition, their overall glucagon content was
unchanged. Interestingly, ISV (10
28 and 10
26 M) counteracted
the palmitate-induced glucagon secretion. Short-term incubation
of a-TC1–6 cells with 0.5 mM palmitate resulted in enhanced
glucagon secretion under conditions of high glucose, while ISV
(10
28 M and 10
26 M) had no effect on glucagon secretion during
short-term incubation. As expected, exposure of murine islets to
0.5 mM palmitate for 72 h resulted in decreased glucose-
stimulated insulin secretion (GSIS) and glucagon hypersecretion.
Our results show that ISV (10
26 M) simultaneously counteracts
the decrease in GSIS and abolishes glucagon hypersecretion from
murine islets. ISV (10
26 M) concomitantly reduces a-cells
proliferation. ISV did not change the TG or glucagon content
of a-cells in the presence of 0.5 mM palmitate. The expression of
Pax6, Pcsk2, Gcg, Irs2, Acaca, Fasn and Srebf2 were up-regulated
during lipotoxicity, while acetyl-Coenzyme A carboxylase beta
(Acacb/ACC2), Insr, Irs1, Pik3r1 and Akt1 remained unchanged.
Interestingly, ISV (10
28,1 0
26 M) significantly increased the
expression of Insr, Irs1, Irs2, Pik3r1 and Akt1 during lipotoxicity.
However, expression of Pax6, Pcsk2, Gcg, Acaca, Acacb, Fasn and
Srebf2 genes were not affected by these conditions. Gcgr
expression was undetected in a-TC1–6 cells but was detected in
liver tissue from mice, using the same Gcgr assay (unpublished
data). Whether or not it is expressed in normal a-cells has yet to be
determined.
We previously demonstrated that, during lipotoxicity, the
glycosylated form of ISV, Stevioside, counteracts the impaired
insulin secretion from both rat islets and INS-1E cells [19].
Stevioside was able to lower blood glucose in type 2 diabetic
subjects [20] and in a non-obese animal model of type 2 diabetes
i.e. the Goto Kakizaki rat [21] by both increasing insulin release
Figure 1. Anti-lipotoxicity and anti-glucotoxicity effects of isosteviol (ISV) in isolated mice islets. Islets were incubated at 11.1 mM
glucose in the presence of 0 mM, 0.5 mM palmitate (Pal) and 0.5 mM Pal with 10
26 M ISV for 72 h. Glucagon (A) and insulin (B) secretion were
measured by incubation of 5 islets with medium containing 18 mM glucose for 2 h. Data is presented as mean 6 SEM (n=18 samples each group
from 3 separate experiments). *P,0.05, **P,0.01, ***P,0.001 vs. control.
#P,0.05 vs. 0.5 mM Pal.
doi:10.1371/journal.pone.0034361.g001
Figure 2. Effects of short-term pretreatment with 10
28 M and
10
26 M ISV on glucagon secretion from palmitate-treated a-
TC1–6 cells. We studied glucagon secretion following 2-hour
incubation with or without 0.5 mM palmitate in the presence or
absence of 10
28 M and 10
26 M ISV in medium containing 18.0 mM
glucose. Data is presented as mean 6 SEM of 24 samples per group
from three independent experiments. One-way ANOVA post hoc
analyses: **P,0.01 vs. 18 mM glucose alone.
doi:10.1371/journal.pone.0034361.g002
Effects of Isosteviol on a-Cells
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dependent effect on insulin secretion and has proven to be more
potent than other ISV derivates found in the plant. ISV improves
blood glucose and insulin sensitivity and upregulates the
expression of key beta-cell genes e.g. Irs1and Pax6 in type 2
diabetic KKAy mice [18].
It is well established that glucagon secretion is regulated by
multiple complex factors including circulating glucose, FFAs,
amino acids, somatostatin, products secreted by b-cells, including
insulin, c-aminobutyric acid (GABA), zinc ions and glutamate, the
central and autonomic nervous systems and several hormones
[14]. However, among these factors, insulin, undoubtedly, plays a
critical role in glucagon secretion [23]. Several in vivo and in vitro
studies have shown that insulin is a major paracrine glucagon
suppressor [24–26], and that an increase in the insulin
concentration suppresses glucagon secretion [27]. Our data also
showed a substantial decrease in Gcg gene expression in a-cells
when co-cultured with b-cells. In fact, insulin inhibits glucagon
secretion via several pathways. Insulin, in a phosphatidylinositol-3
(PI-3) kinase-dependent manner, stimulates mouse islet a- and b-
cell KATP channel opening by decreasing their sensitivity to ATP
block [28]. Furthermore, insulin increases KATP channel activity
in isolated rat a-cells via membrane hyperpolarization [24]. In
addition to the effects on KATP channels, insulin has been reported
to activate A-type GABA receptors in the a-cells by receptor
translocation via activation of Akt i.e. a critical downstream
effector of PI3K. This leads to membrane hyperpolarization in the
a-cells and thus suppression of glucagon secretion [29]. Insulin
also acts in the ventromedial hypothalamus via activation of the
PI3K signalling pathway to influence and possibly fine-tune- the
release of pancreatic glucagon, under both hypoglycemic and
fasting conditions [30].
To further elucidate potential mechanisms whereby ISV
regulates glucagon secretion, we utilised the clonal pancreatic a-
cell line, a-TC1–6 cells. These cells show characteristics of native
islet a-cells, but do not produce insulin and somatostatin at
detectable levels [31]. It is our understanding that this is the first
study reporting effects of ISV on glucagon secretion from
palmitate-exposed a-cells. Here we demonstrated that short-term
exposure of a-cells to elevated palmitate induced glucagon
hypersecretion. Although short-term exposure to ISV (10
28 M
and 10
26 M) had no effect on glucagon secretion, long-term
incubation with ISV (10
28 M and 10
26 M) resulted in a
significant reduction in glucagon hypersecretion elicited by
palmitate. It is noteworthy that ISV (10
28 M and 10
26 M), in
the presence of palmitate, also enhanced Insr, Irs1, Irs2, Pik3r1
and Akt1 expression. The highest ISV dose (10
26 M) elicited more
pronounced changes in gene expression than the lower dose in the
absence of palmitate (Fig. 5A–5L). However, when palmitate was
added, the differences in gene expression at various ISV doses
faded. The reason for this is not known.
In addition to failure of b cells to secrete insulin, the a-cell
dysfunction in type 2 diabetes seems to result from insulin
resistance of these glucagon-producing cells [27]. Insr and its
downstream signaling proteins are abundantly expressed in
pancreatic a-cell lines [32]. The high level of Insr expression by
a-cells suggests that these cells are also important sites of insulin
action [24]. In studies of glucagon-secreting InR1G cells and a-
TC6 cells, Insr knockdown (using siRNA) not only enhanced
glucagon secretion [33,34], but also reduced cell growth [34].
Adult male a-cell specific Insr knockout (aIRKO) mice have been
shown to exhibit mild glucose intolerance, hyperglycemic and
hyperglucagonemia in the fed state and enhanced glucagon
secretion in response to L-arginine stimulation which led to
increased glucose release from the liver. Moreover, aIRKO mice
Figure 3. The inhibitory effects of long-term pre-treatment (72 h) with ISV on palmitate-induced glucagon secretion. a-TC1–6 cells
were incubated, for 72 h, with or without 0.5 mM palmitate (Pal) (gray bars, without Pal; black bars, with Pal) in the presence or absence of ISV (10
28
to 10
26 M). The cells were then incubated in medium containing 2 mM glucose (A) or 18 mM glucose (B) for 2 h. Data is presented as mean 6 SEM
of 18–20 samples per group from three independent experiments. One-way ANOVA post hoc analyses: *P,0.05, **P,0.01 compared with glucose
alone.
#P,0.05 compared with Pal alone.
doi:10.1371/journal.pone.0034361.g003
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In a-cells, the activation of Insr/Irs1/Pi3k/Akt may eventually
lead to membrane hyperpolarization, regulate K-channel sensi-
tivity to ATP and reduce glucagon release [35]. Extended
exposure of a-cells to insulin has been shown to result in Insr
downregulation and loss of insulin-regulated inhibition of glucagon
gene transcription [36]. Together, these data indicate a substantial
role for intra-islet insulin signaling in the regulation of a-cell
function. a-cell studies are consistent with a large number of
studies of insulin action on its classic target tissues. Insulin is known
to regulate pancreatic b-cell function through the activation of cell
surface Insr, phosphorylation of Irs1 and Irs2, and activation of
Pi3k [37]. Piro S, et al. [38] recently reported that palmitate
affected Insr phosphorylation and intracellular insulin signalling in
a-TC1–6 cells, while insulin-stimulated phosphorylation of Insr,
Irs-1, Pi3K and Akt were greatly reduced under the same
conditions. In a-cells, insulin has been reported to inhibit glucagon
release and Gcg gene expression, through phosphorylation of Irs1
and activation of Pi3k [39].
Prohormone convertase 2 (PC2, also referred to as Pcsk2) is the
enzyme responsible for processing proglucagon to the active
glucagon in pancreatic a-cells [40]. Mice deficient in PC2 have
little or no mature circulating glucagon [41]. Pax6, is an important
gene for glucagon biosynthesis. It controls some key genes involved
in Gcg gene transcription, proglucagon processing enzyme PC2
[42,43], and a cell differentiation [42]. Therefore, we further
explored whether ISV affects Gcg gene transcription in the
presence of palmitate. Pax6, Pcsk2 and Gcg gene expression levels
were found to be higher in a-TC1–6 cells cultured with palmitate.
A similar observation has previously been reported [38]. No
changes were found in expression levels of Pax6, Pcsk2 and Gcg
with ISV in the presence of palmitate. Although ISV alone
increased expression of Pax6, Pcsk2 and Gcg genes related to
glucagon biosynthesis, ISV did not alter glucagon secretion. This
may be due to upregulation of other key regulatory genes such as
Insr, Irs1, Irs2, Pik3r1 and Akt1 which inhibit glucagon secretion.
The diverging actions observed may have balanced out each other
leading to no net change in the secretion of glucagon in the
presence of ISV alone (Fig. 3).
Besides the regulation of glucagon secretion, a-cell growth and
survival are of increasing interest in diabetes research. Liu et al.
reported that elevated plasma glucose levels in diabetic mice is
accompanied by increased pancreatic a-cell numbers [44]. We
have established that ISV inhibited a-cell proliferation in the
presence of 0.5 mM palmitate. Mizushina et al. reported that ISV
inhibited human cancer cell growth [45]. The precise mechanisms
responsible for these alterations remain to be clarified. It is
puzzling that palmitate also decrease a-cell proliferation, which
may be due to lipotoxicity [12].
In the present study we demonstrated that long-term exposure
to palmitate resulted in TG accumulation in a-cells and increased
expression of genes that are involved in fatty acid synthesis and
oxidation i.e. Fasn, Acaca and Srebf2. ISV was found not to reduce
TG content and/or alter the expression of fatty acid metabolism-
related genes in the presence of palmitate. Surprisingly, we found
no change in the glucagon content of a-TC1–6 cells in presence of
palmitate. This is, however, in line with Hong et al. [17] who also
Figure 4. Impact of ISV on glucagon content, TG content, and
3H-thymidine incorporation in a-TC1–6 cells. After 72 h pre-
treatment with or without 0.5 mM palmitate (Pal) in the presence or
absence of ISV 10
28 M and 10
26 M; illustrating glucagon content, TG
content and
3H-thymidine incorporation in a-TC1–6 cells. Data is
presented as mean 6 SEM; n=10–12 per group in glucagon content
(A) and n=21–24 per group in TG content (B), whereas data in
3H-
thymidine incorporation (C) are expressed as a relative ratio compare to
control group of n=30 per group from three independent experiments.
*P,0.05, **P,0.01 vs. control.
#P,0.05 vs. Pal.
doi:10.1371/journal.pone.0034361.g004
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the glycosylated form of ISV.
In summary, our study demonstrates that chronic exposure to
palmitate inhibits insulin secretion, increases glucagon secretion
from murine islets and from a-TC1–6 cells, while increasing Pax6,
Pcsk2 and Gcg gene expression and TG accumulation. The
inhibitory effect of ISV on excess glucagon secretion from murine
islets may be due to augmentation of GSIS, which suppresses
glucagon secretion. Evidence suggests that the effect of ISV on a-
TC1–6 cells may be related to enhanced expression of key
regulatory genes involved in insulin signal transduction pathways,
thereby increasing insulin sensitivity in a-cells, and concomitantly
counteracting hyperglucagonemia. As ISV possesses insulinotropic
and glucagonostatic effects, it is likely that ISV may serve as a
valuable new therapeutic agent in type 2 diabetes. To further
confirm ISV antihyperglycemic effects, clinical trials including
consenting people with type 2 diabetes are now warranted.
Materials and Methods
Reagents and buffers/solutions
Agent preparation. All chemicals were purchased from
Sigma-Aldrich (Brøndy, Denmark) if not stated otherwise.
Isosteviol (ISV) (ent-16-ketobeyeran-19-oic acid; Wako Pure
Chemical Industries, Osaka, Japan) was added to the medium
from a stock solution (10
23 M) prepared in 99% ethanol.
50 mmol/l palmitate: The solution was prepared as previously
described [17]. Palmitate (Sigma, St. Louis, Mo) was prepared by
dissolving and heating equal molar amounts of NaOH and fatty
acids, supplemented with distilled water, to obtain a 500 mM
concentration. It was further diluted with 5% bovine serum
albumin (BSA) (fatty acid free, Sigma) to 50 mM fatty acid. The
stock solution was stored at 220uC.
Modified Krebs-Ringer Buffer (M-KRB): 125 mM NaCl,
5.9 mM KCl, 1.2 mM MgCl2, 1.28 mM CaCl2, 5.0 mM
NaHCO3, 25 mM HEPES (pH 7.4).
SYTO 24 solution: 5 mM SYTO 24 green fluorescent nucleic
acid stain (molecular probes, Invitrogen, Oregon, USA) was
dissolved in dimethyl sulfoxside $99.9% to a final concentration
of 0.01 mM.
Experimental animals
Adult female Naval Medical Research Institute (NMRI) mice
(Bomholtgaard Breeding and Research Center, Ry, Denmark)
were maintained on a 12-h light/dark cycle and had free access to
water and an ordinary laboratory chow diet. At the time of
experiments, they had similar body weights (31–38 g). This study
was approved by the Danish Council for Animal Experiments
(2010/561-1805).
Islet Isolation
Islets were isolated by the collagenase digestion technique [46].
In brief, the animals were anaesthetized with pentobarbital
(50 mg/kg intraperitoneally) and midline laparotomy was per-
formed. The pancreas was retrogradely filled with 3 ml ice-cold
Hanks balanced salt solution (HBSS) (Sigma Chemical, St Louis,
MO, USA) supplemented with 0.3 mg/ml collagenase P (Boeh-
ringer Mannheim, Mannheim, Germany). HPSS and collagenase
P was filter-sterilized before use. The pancreas was subsequently
removed and incubated for 19 min at 37uC in a water-bath, and
rinsed with ice-cold HBSS. The islets were subsequently
handpicked under a stereomicroscope. The islets were then
incubated overnight at 37uC and 95% normal atmosphere/5%
CO2 in 10 ml RPMI 1640 containing 11.1 mmol/l glucose
supplemented with 10% fetal bovine serum (FBS), 2.06 mM L-
glutamine, 100 IU/ml penicillin G and 100 mg/ml streptomycin
(all from GIBCO BRL, Paisley, UK). In each experiment, islets
were obtained from 8–10 mice to compensate for inter-individual
differences.
Islet insulin and glucagon secretion studies
This part of the studies aimed to determine whether ISV could
prevent lipotoxicity caused by palmitate in mice islets. After
overnight culture, the islets were incubated in 4-well plates
(NUNC) with fresh medium. Thus, ten islets were incubated in
1 ml RPMI 1640 containing 11.1 mM glucose in the absence or
presence of 0.5 mM palmitate, and with 0.5 mM palmitate plus
ISV (10
26 M). Palmitate solution (0.5 mM) was freshly prepared
before each experiment.
After 72 h culture, the islets were rinsed once with M-KRB
supplemented with 11.1 mM glucose and 0.5% BSA (fatty acid
Figure 5. Effects of palmitate and ISV on gene expression. After 72 h of treatment with or without 0.5 mM palmitate (Pal) in the presence or
absence of ISV 10
28 M and 10
26 M, gene expression levels in a-TC1–6 cells were determined and normalized to Hprt. Data is expressed as relative
level to control (n=10–12 samples in each group, RNA extracted from three independent experiments). *P,0.05, **P,0.01, *** P,0.001 vs. control.
#P,0.05,
##P,0.01 vs. 0.5 mM Pal.
doi:10.1371/journal.pone.0034361.g005
Figure 6. Effects of a-TC1–6 cells and or MIN6 cells on gene expression. Ins1 (A) and Ins2 (B) expression in MIN6 cells when cultured, for
72 hours, alone or in combination with a-TC1–6 cells. Gcg (C) expression in a-TC1–6 cells cultured, for 72 hours, alone or in combination with MIN6
cells. All data are expressed as relative level to control (n=6 samples per group). **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0034361.g006
Effects of Isosteviol on a-Cells
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e34361free, BSA from Roche, Mannheim, Germany). Consequently,
batches of five islets were handpicked and incubated in a 37uC
water bath with 250 ml of M-KRB containing 0.5% BSA with
18 mM glucose. After 2 h, 150 ml of incubation medium from five
islets was collected on ice and frozen for the subsequent analysis of
glucagon and insulin secretion. The results of glucagon and insulin
were expressed as pg/ml/5 islets, and ng/ml/5 islets, respectively.
Glucagon and insulin were analysed by radioimmunoassay
(detailed below).
a-TC1–6 cell and culture conditions
The a-TC1 cell line was derived from an adenoma developed in
transgenic mice expressing the SV40 large T-antigen oncogene
[31]. The a-TC1 subclone 6 (a-TC1–6 cells, courtesy of Prof.
Shimon Efrat, Tel Aviv University, Israel) cells between passages
16 and 49 were grown in Dulbecco’s Modified Eagle’s Medium
(DMEM) (GIBCO-BRL, Paisley, UK) containing 18 mM glucose
and 10% FBS (GIBCO-BRL) at 37uC in a humidified (5% CO2,
95% air) atmosphere. Cells were passaged once a week and
replaced with fresh medium twice weekly. These were seeded at
0.25610
6 cells/well (24-well plate) and 0.75610
6 cells/well (6-well
plate) 24 h before an assay.
Glucagon secretion from a-TC1–6 cells
Short-term incubation. a-TC1–6 cells were pre-incubated,
for 15 min, in Krebs-Ringer buffer (KRB) and 0.5% BSA (pH 7.4)
and were subsequently incubated for 2 h with KRB containing
18 mM glucose in the presence or absence of 10
28 M and
10
26 M ISV, 0.5% BSA, 0.5 mM palmitate with or without
10
28 M and 10
26 M ISV at 18 mM glucose. Subsequently,
supernatants (300 ml each) were collected, centrifuged, and 200 ml
supernatants were kept frozen at 220uC for glucagon analysis.
Protein assay
After the acute secretion study, the medium was removed and
cells were lysed in 0.1 M NaOH (Sigma). Intracellular protein was
measured by Bio-Rad detergent compatible protein assay kit (Bio-
Rad Laboratories, Hercules, CA). The glucagon levels in short-
term a-TC1–6 cells incubation were adjusted to protein
concentration.
Long-term incubation
a-TC1–6 cells were incubated for 72 h at 37uC in DMEM with
18 mM glucose in the presence or absence of 0.5 mM palmitate
(Sigma Chemical, St. Louis, MO), 0.5% BSA (fatty acid free;
Roche, Mannheim, Germany) with or without 10
28 to 10
26 M
ISV. Palmitate solution (0.5 mM) was freshly prepared before each
experiment.
After 72 h, the cells were pre-incubated for 15 min in KRB and
0.5% BSA (pH 7.4) and were then incubated for 2 h with KRB
containing 2 or 18 mM glucose and 0.5% BSA. Subsequently, as
before, supernatants (300 ml) were collected, centrifuged and
200 ml were stored at 220uC for glucagon analysis. After the
secretion study, the cells were washed once with 1 ml dH2O and
the number of cells was estimated using nuclear staining with
0.01 mM SYTO 24 reagent (20 ml/well, Roche) and measured by
FLUOstar Galaxy (BMG, Ramcon, Denmark). Glucagon levels
were normalized to cell number.
Glucagon content
Cells were exposed, for 72 h, to DMEM containing 18 mM
glucose with or without 0.5 mM palmitate as well as ISV (10
28 or
10
26 M) in six-well plates as 3 ml/well. These culture conditions
were used in all subsequent studies with the a-TC1–6 cell line,
except where otherwise stated. The cells were washed once with
2 ml of cold PBS (GIBCO), replaced by 1 ml of glycine-BSA
(glycine 100 mM, 0.25% BSA, pH 8.8; both Sigma) and were
then transferred to 1.5 ml tubes. a-cells were disrupted by
sonication (Branson Sonifier 250, Danbury, CT) on ice for 15 s
(twice). After centrifugation at 16,000 rpm for 30 min, the
supernatants were collected and stored at 220uC for glucagon
and protein assay. Glucagon content levels were adjusted to
protein concentration. Intracellular protein was measured by Bio-
Rad detergent compatible protein assay kit (Bio-Rad Laboratories,
Hercules, CA).
Insulin assay
Insulin was analyzed by radioimmunoassay using guinea pig
anti-porcine insulin antibody (Novo Nordisk, Bagsvaerd, Den-
mark) and mono-125I-(Tyr A14)-labeled human insulin (Novo
Nordisk) as tracer and rat insulin as standard (Novo Nordisk).
Bound and free radioactivity was separated by ethanol. The inter-
and intra-assay variation coefficients were both less than 5%. ISV,
like Stevioside and steviol at the concentrations studied, did not
interfere with the insulin assay [46].
Glucagon assay
Glucagon was analyzed by radioimmunoassay kit (Millipore
Research Park Drive, St Charles, Missouri USA) according to
manufacturer’s instructions. The glucagon antibody is specific for
pancreatic glucagon and has no cross-reaction with other islet
polypeptides. The limit of sensitivity for the glucagon assay is
20 pg/mL.
TG content
To determine TG content, cells were seeded in 24-well plates.
After 72 h, the medium was removed, the cells were washed once
with 1.0 ml of 0.9% NaCl, and the number of cells was estimated
as above. The cells were frozen and stored for 1 h at 280uC.
Subsequently, cells were incubated for 20 min with TG reagents
(Roche; 250 ml/well). TG content was determined by a TG GPO-
PAP kit (Roche) and was normalized to cell number. The recovery
of TG content was ,90%.
3H-thymidine incorporation in a-TC1–6 cells
3H-thymidine incorporation was used to monitor a-TC1–6 cells
proliferation and DNA synthesis [47]. Briefly, cells (4610
4 cells/
well) were seeded in 96-well plates (Wallac Oy, Turku) and were
cultured in DMEM containing 18 mM glucose and 10% FBS.
The next day, the medium was replaced with DMEM containing
5.5 mM glucose, 0.1% BSA and without FBS for 24 h (i.e. serum
deprivation). The cells were then cultured for a further 72 h in
DMEM containing 0.5% BSA, 18 mM glucose and 0.5 mM
palmitate and 1 mCi [methyl-
3H] thymidine (Amershan, Biosci-
ences, UK). After 72 h, the cells were washed twice in cold PBS
and then 200 mL liquid scintillator was added. The incorporated
[methyl-
3H] thymidine was counted by a 1450 MicroBeta
TRILUX (Wallac, Turku, Finland).
Isolation of RNA
The a-TC1–6 cells were cultured in 6-well plate for 72 h (as
described in ‘‘Glucagon content’’) prior to RNA extraction.
The MIN-6 cells (generously donated by Dr. Yamamoto,
Kumamoto University school of Medicine, Japan) produce insulin
and have morphological characteristics of pancreatic b-cells [31].
MIN6 cells between passages (38–40) were cultured separately in
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The cells were passaged weekly after trypsinization and replen-
ished with fresh media. The cells are seeded in 6-well plates as
25% a-TC1–6 cells and 75% MIN6 cells; 100% a-TC1–6 cells; or
100% MIN6 cells.
Cells were then washed once with cold PBS and RNA was
extracted from three different passages of cells using the AllPrepH
RNA/Protein kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. RNA was quantified by measuring
absorbance at 260 and 280 nm (NanoDrop ND-8000 UV-Vis
Spectrophotometer, NanoDrop Technologies Wilmington, DE).
The integrity of the RNA was checked by visual inspection of the
two ribosomal RNAs, 18S and 28S bands on a 1% non-denaturing
agarose gel, stained with SYBR green.
Real-time RT-PCR
Reverse transcription (RT): cDNA was synthesized, from 1 mg
of total RNA for each 20 ml RT reaction, using the iScript
TM
cDNA synthesis Kit (Bio-Rad, Hercules, CA, USA) according to
the manufacturer’s instructions. cDNA was assayed undiluted for
Acacb and diluted (1:8) for Pax6, Pcsk2, Gcg, Insr, Irs1, Irs2,
Acaca, Fasn, Srebf2, Pik3r1, Akt1 and Hypoxanthine guanine
phosphoribosyl transferase (Hprt) in a-TC1–6 cells alone, (1:100)
for Ins1, Ins2, Gcg and Hprt in 25% a-TC1–6 and 75% MIN6
cells, both or just one or the other.
Real-time PCR (qPCR) was subsequently performed using
TaqManH assays using an ABI 7500 FAST machine (ABI, Foster
City, CA, USA). Predesigned TaqManH probes and primers were
obtained from Applied Biosystems (ABI, Foster City, CA, USA)
for Pax6 (assay Mm00443072_m1), Pcsk2(assay
Mm00500981_m1), Gcg(assay Mm00801712_m1), Insr(assay
Mm00439693_m1), Irs1(assay Mm01278327_m1), Irs2(assay
Mm03038438_m1), Acaca(assay Mm01304277_m1), Acacb(assay
Mm01204678_m1), Fasn(assay Mm00662319_m1), Srebf2(assay
Mm01306289_m1), Pik3r1(assay Mm01282781_m1), Akt1(assay
Mm01331624_m1), Ins1(assay Mm01259683_g1), Ins2(assay
Mm00731595_gH) and Gcgr(assay Mm00433546_m1). Hprt(as-
say Mm01318743_m1) was assessed as endogenous control.
In brief, 10 ml reactions were prepared consisting of 5 ml2 6
TaqMan HFAST Universal Master Mix (P/N 4367846; ABI;
Foster City, CA, USA), 0.5 ml2 0 6TaqMan Assay mix/probe
(ABI; Foster City, CA, USA), 3.5 ml AcuGENE H2O and 1 ml
cDNA (diluted or undiluted as above). Thermal FAST cycle
programme was run at 95uC for 20 s; followed by 40 cycles at
95uC for 3 s and at 60uC for 30 s. Reactions were set up in
duplicate for each sample and target gene expression levels were
normalized to Hprt expression. All assays were performed in 96-
well format plates (P/N 4366932) covered with optical adhesive
cover (P/N 4311971; ABI; Foster City, CA). The TaqMan assay
efficiencies were calculated to be in the range 89–108%. The
2
2DDct method was applied to calculate the relative gene
expression [48]. No template controls were included for each
gene, as negative controls.
Data and statistical analyses
Data is expressed as mean 6 SEM of three or four independent
experiments. Data analysis and graphs were performed using
GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA,
USA). Statistical significance between two groups was evaluated by
a two-tailed Student’s unpaired T-test. One-way ANOVA
followed by Dunnett’s or Tukey post hoc tests (when appropriate)
was used to detect statistically significant differences when more
than two groups were compared. P,0.05 was considered to be
significant.
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